Getting a GLP-1 covered: prior authorization, appeals and your options

Why GLP-1 coverage is complicated

Each brand is approved for specific uses, and plans cover by approved use. Ozempic and Mounjaro are approved for type 2 diabetes. Wegovy, Zepbound and Foundayo are approved for weight management, which a plan may exclude or cover only as an optional benefit that an employer chooses to buy; Wegovy is also approved to lower heart attack and stroke risk in people with heart disease, and Zepbound for obstructive sleep apnea in adults with obesity, and those approvals can open coverage where weight management alone would not.

Prescribing a diabetes brand for weight loss alone is an off-label use, which is not FDA-approved; a prescriber may legally decide it is appropriate, but a plan can decline to pay for a use outside its coverage criteria, and pharmacies may ask about it. The cleanest route is a prescription for the brand approved for your condition.

Find out exactly what your plan covers

Before the prescription is written, look up the drug in your plan’s formulary, the list of covered drugs; check the insurer’s website or member portal, or call the number on your card. Note whether it is covered, which tier it is on, and whether it carries prior authorization, step therapy or quantity limits. If weight-management drugs are not listed at all, ask the plan whether they are excluded; for coverage through work, ask your employer’s benefits team, since self-funded employer plans decide their own exclusions.

Ask for the plan’s written criteria for approval. Criteria can follow the FDA labels, which for weight management cover adults with a body mass index of 30 or more, or 27 or more with a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or sleep apnea, alongside diet and activity. A plan may also ask for documented prior attempts at weight loss, and for renewal it may require a minimum amount of weight lost by a set point.

How prior authorization works

Prior authorization means the plan approves the drug before it pays. The prescriber’s office submits a request with your diagnosis, your measurements, relevant conditions and lab results, and the treatments you have tried. Approvals can be time-limited, so put the renewal date in your calendar and ask the office to start the renewal early, with your progress documented.

• Your current weight, height and body mass index, with dates.
• Weight-related conditions, such as high blood pressure, prediabetes or diabetes, high cholesterol, sleep apnea or heart disease.
• Prior weight-loss efforts, including programs, diet changes and medicines tried.
• For diabetes, recent A1c results and the diabetes medicines tried.
• For a sleep apnea or heart indication, the sleep study or the cardiac diagnosis.

What to do after a denial

Read the denial letter carefully: it must state the reason and how to appeal. If the denial is about missing information rather than eligibility, resubmitting with the missing documents can be enough. If not, your prescriber can ask for a peer-to-peer review, a conversation with the plan’s reviewing clinician, where the plan offers one.

You also have the right to a formal internal appeal, with a letter of medical necessity from your prescriber explaining why the drug is needed and why covered alternatives are not suitable. If the plan upholds the denial, you have the right to ask for an independent external review by a reviewer outside the insurer, as HealthCare.gov explains. A plan exclusion is different from a medical-necessity denial: the plan’s terms leave the drug out, so an appeal about medical need may not change it; then the conversation is with your employer about adding the benefit, or about the paying options below.

Medicare and Medicaid

Federal law excludes drugs used only for weight loss from Medicare Part D, but Part D plans cover GLP-1 medicines for type 2 diabetes, and can cover Wegovy to lower cardiovascular risk in people with heart disease and Zepbound for obstructive sleep apnea, and a plan may require prior authorization. From July 2026 to the end of 2027, the Medicare GLP-1 bridge program lets eligible Part D enrollees get certain obesity GLP-1 medicines for a flat monthly copay. Part D coverage determinations follow set deadlines, faster when waiting could seriously harm your health, and appeals can go to independent review.

Medicaid coverage of weight-management GLP-1s varies by state and can change from year to year, so check your state Medicaid plan’s preferred drug list, which also shows any prior authorization for diabetes use.

If the answer is still no

Several routes remain. Novo Nordisk sells Wegovy and Ozempic directly to self-paying patients through NovoCare Pharmacy, and Eli Lilly sells Zepbound and Foundayo through LillyDirect, at prices that depend on the dose, so compare them with any pharmacy quote for the brand; the TrumpRx website also lists offers for some of these drugs. Generic liraglutide, the older daily GLP-1, is a different medicine your prescriber may consider, and pharmacies set their own cash prices for it, so comparing quotes helps. Money in a health savings account or flexible spending account can pay for a GLP-1 prescribed to treat obesity or diabetes.

Avoid unverified online sellers. Since the shortages ended, compounded copies are allowed only in narrow circumstances, and products sold without a prescription or as research chemicals are neither legal nor safe.

Staying covered over time

Coverage can change. A plan can change its formulary for a new plan year, an employer can add or drop a weight-management benefit, and renewals can depend on documented progress. Keep a record of your weight, measurements and lab results, check your plan’s formulary before each open enrollment, and ask your prescriber to start renewals early. If your plan changes, a switch to another covered GLP-1 is sometimes possible, but doses are not directly equivalent, so the prescriber chooses the new starting dose.